Moderna Financial Statements From 2010 to 2026

MRNA Stock  USD 51.71  0.34  0.66%   
Moderna's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Moderna's valuation are provided below:
Gross Profit
-2.1 B
Profit Margin
(1.45)
Market Capitalization
20.2 B
Enterprise Value Revenue
2.1762
Revenue
1.9 B
We have found one hundred twenty available fundamental ratios for Moderna, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Moderna last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 37.6 B. The current year's Enterprise Value is expected to grow to about 35.4 B

Moderna Total Revenue

1.85 Billion

Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as Interest Expense of 29 M, Selling General Administrative of 1.2 B or Total Revenue of 1.8 B, as well as many indicators such as Price To Sales Ratio of 5.61, Dividend Yield of 4.0E-4 or PTB Ratio of 1.26. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
  
Build AI portfolio with Moderna Stock
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Moderna Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10 B12.3 BB
Slightly volatile
Total Current Liabilities2.4 BB1.7 B
Slightly volatile
Other Liabilities975.7 M929.2 M365.4 M
Slightly volatile
Accounts Payable196 M317 M137.8 M
Slightly volatile
Cash1.9 B2.6 B1.4 B
Slightly volatile
Net Receivables174.8 M184 M502.9 M
Slightly volatile
Other Current Assets296.3 M408 M192.4 M
Slightly volatile
Total Liabilities3.2 B3.7 B2.3 B
Slightly volatile
Deferred Long Term Liabilities1.9 M2.1 M2.3 M
Slightly volatile
Total Current AssetsB6.5 B4.2 B
Slightly volatile
Intangible Assets48.3 M46 M25.8 M
Slightly volatile
Other Current Liabilities921.1 M1.6 B596 M
Slightly volatile
Common Stock Shares Outstanding360.8 M389 M251.4 M
Slightly volatile
Short and Long Term Debt TotalB1.9 B521.6 M
Slightly volatile
Property Plant And Equipment Net1.4 B2.9 B883.7 M
Slightly volatile
Current Deferred Revenue94 M99 M829.1 M
Pretty Stable
Non Current Assets Total4.8 B5.8 BB
Slightly volatile
Non Currrent Assets Other635.2 M605 M194.4 M
Slightly volatile
Other Assets1.6 B2.2 BB
Slightly volatile
Long Term Debt15.5 M18 M14.5 M
Slightly volatile
Cash And Short Term Investments5.6 B5.8 B3.7 B
Slightly volatile
Short Term Investments3.3 B3.2 B2.3 B
Slightly volatile
Long Term Debt Total27.6 M44.5 M25.9 M
Slightly volatile
Liabilities And Stockholders Equity12 B12.3 B7.6 B
Slightly volatile
Non Current Liabilities Total995.4 M1.7 B736.4 M
Slightly volatile
Capital Surpluse2.4 B1.3 B1.3 B
Slightly volatile
Capital Lease Obligations526.9 M859 M339.5 M
Slightly volatile
Other Stockholder Equity1.8 B1.4 B1.1 B
Slightly volatile
Long Term Investments2.9 B2.9 B1.8 B
Slightly volatile
Short and Long Term Debt1.4 M2.2 M1.4 M
Slightly volatile
Preferred Stock Total Equity941.3 M1.1 B1.2 B
Slightly volatile
Non Current Liabilities Other39.3 M41.4 M135.3 M
Slightly volatile
Short Term Debt40.4 M42.5 M57.5 M
Slightly volatile
Property Plant Equipment2.6 B2.5 B849.2 M
Slightly volatile
Common Stock Total Equity31.1 K46 K23.1 K
Slightly volatile
Property Plant And Equipment Gross4.2 BB1.2 B
Slightly volatile
Net Working Capital4.6 B6.8 B2.9 B
Slightly volatile

Moderna Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative1.2 B1.2 B406.3 M
Slightly volatile
Other Operating Expenses3.7 BB2.6 B
Slightly volatile
Research Development1.9 B3.1 B1.3 B
Slightly volatile
Net Interest Income484.2 M461.1 M123.3 M
Slightly volatile
Interest Income513.2 M488.8 M131.4 M
Slightly volatile
Depreciation And Amortization190.1 M215 M118.1 M
Slightly volatile
Reconciled Depreciation189.2 M217.3 M113.3 M
Slightly volatile
Preferred Stock And Other Adjustments13.7 M15.4 M16.8 M
Slightly volatile
Selling And Marketing Expenses172.7 M167.9 M133.2 M
Slightly volatile

Moderna Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation158.4 M215 M111 M
Slightly volatile
End Period Cash Flow2.1 B2.6 B1.4 B
Slightly volatile
Stock Based Compensation507.1 M483 M156.1 M
Slightly volatile
Begin Period Cash Flow2.1 B1.9 B1.3 B
Slightly volatile
Dividends Paid326 M310.5 M88.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.615.90119.8095
Very volatile
Dividend Yield4.0E-42.0E-44.0E-4
Slightly volatile
PTB Ratio1.261.32623.716
Pretty Stable
Days Sales Outstanding32.8234.547392.3757
Very volatile
Book Value Per Share16.0222.236517.3573
Slightly volatile
Stock Based Compensation To Revenue0.330.24850.3243
Pretty Stable
Capex To Depreciation0.850.8932.0592
Pretty Stable
PB Ratio1.261.32623.716
Pretty Stable
EV To Sales5.275.551818.9822
Very volatile
Inventory Turnover6.645.67323.809
Slightly volatile
Days Of Inventory On Hand61.1264.3376309
Slightly volatile
Payables Turnover3.522.73822.9872
Slightly volatile
Sales General And Administrative To Revenue0.620.370.483
Pretty Stable
Research And Ddevelopement To Revenue2.411.61112.3224
Pretty Stable
Capex To Revenue0.09380.09880.2633
Slightly volatile
Cash Per Share11.6814.907515.1045
Very volatile
Days Payables Outstanding232133378
Slightly volatile
Intangibles To Total Assets0.00470.00590.0053
Slightly volatile
Current Ratio4.623.29345.0983
Slightly volatile
Tangible Book Value Per Share15.9822.236517.326
Slightly volatile
Receivables Turnover11.0910.56526.5922
Slightly volatile
Shareholders Equity Per Share16.0222.236517.3573
Slightly volatile
Debt To Equity0.230.22150.0643
Slightly volatile
Capex Per Share0.650.49360.6953
Slightly volatile
Graham Net Net5.45.97817.0193
Very volatile
Revenue Per Share4.754.99748.4121
Slightly volatile
Interest Debt Per Share5.174.92541.3812
Slightly volatile
Debt To Assets0.160.15530.0428
Slightly volatile
Graham Number169175156
Slightly volatile
Operating Cycle93.9498.8849144
Pretty Stable
Price Book Value Ratio1.261.32623.716
Pretty Stable
Days Of Payables Outstanding232133378
Slightly volatile
Ebt Per Ebit1.050.90050.9617
Very volatile
Company Equity Multiplier1.771.42641.6434
Pretty Stable
Long Term Debt To Capitalization0.10.110.1232
Slightly volatile
Total Debt To Capitalization0.190.18130.0572
Slightly volatile
Debt Equity Ratio0.230.22150.0643
Slightly volatile
Quick Ratio4.553.21645.0613
Slightly volatile
Net Income Per E B T0.791.01950.982
Pretty Stable
Cash Ratio1.191.3060.8114
Slightly volatile
Days Of Inventory Outstanding61.1264.3376309
Slightly volatile
Days Of Sales Outstanding32.8234.547392.3757
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.851.10250.8519
Slightly volatile
Price To Book Ratio1.261.32623.716
Pretty Stable
Fixed Asset Turnover0.650.68142.3756
Pretty Stable
Debt Ratio0.160.15530.0428
Slightly volatile
Price Sales Ratio5.615.90119.8095
Very volatile
Asset Turnover0.220.15760.198
Slightly volatile
Price Fair Value1.261.32623.716
Pretty Stable

Moderna Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap37.6 B35.9 B17.6 B
Slightly volatile
Enterprise Value35.4 B33.7 B16.6 B
Slightly volatile

Moderna Fundamental Market Drivers

Forward Price Earnings32.4675
Cash And Short Term Investments5.8 B

Moderna Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Moderna Financial Statements

Moderna stakeholders use historical fundamental indicators, such as Moderna's revenue or net income, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue99 M94 M
Total Revenue1.9 B1.8 B
Cost Of Revenue868 M1.5 B
Stock Based Compensation To Revenue 0.25  0.33 
Sales General And Administrative To Revenue 0.37  0.62 
Research And Ddevelopement To Revenue 1.61  2.41 
Capex To Revenue 0.10  0.09 
Revenue Per Share 5.00  4.75 
Ebit Per Revenue(1.58)(1.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. Expected growth trajectory for Moderna significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Moderna assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.85)
Earnings Share
(7.26)
Revenue Per Share
4.997
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.15)
Understanding Moderna requires distinguishing between market price and book value, where the latter reflects Moderna's accounting equity. The concept of intrinsic value - what Moderna's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Moderna's price substantially above or below its fundamental value.
Understanding that Moderna's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moderna represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Moderna's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.